Syntex phasing out Hamilton Pharma generics subsidiary; Upjohn sticking with Greenstone.

Executive Summary

ROCHE/SYNTEX PHASING OUT HAMILTON PHARMA GENERICS BUSINESS "because it no longer fits with the strategic focus in the U.S. of Syntex," the company said Jan. 17. Syntex launched the Hamilton line in late 1993 to introduce generic versions of its flagship nonsteroidal anti-inflammatory drugs Naprosyn (naproxen) and Anaprox (naproxen sodium). The company subsequently introduced versions of the oral contraceptive Levora (levonorgestrel/ethinyl estradiol) and the topical corticosteroid Lidex (fluocinonide). Syntex was acquired by Roche in September.